Tumor-Derived Extracellular Vesicles Require β1 Integrins to Promote Anchorage-Independent Growth.
Biological Sciences
Cancer
Cell Biology
Molecular Biology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
26 Apr 2019
26 Apr 2019
Historique:
received:
21
11
2018
revised:
14
02
2019
accepted:
21
03
2019
pubmed:
14
4
2019
medline:
14
4
2019
entrez:
14
4
2019
Statut:
ppublish
Résumé
The β1 integrins, known to promote cancer progression, are abundant in extracellular vesicles (EVs). We investigated whether prostate cancer (PrCa) EVs affect anchorage-independent growth and whether β1 integrins are required for this effect. Specifically using a cell-line-based genetic rescue and an in vivo PrCa model, we show that gradient-purified small EVs (sEVs) from either cancer cells or blood from tumor-bearing TRAMP (transgenic adenocarcinoma of the mouse prostate) mice promote anchorage-independent growth of PrCa cells. In contrast, sEVs from cultured PrCa cells harboring a short hairpin RNA to β1, from wild-type mice or from TRAMP mice carrying a β1 conditional ablation in the prostatic epithelium (β1
Identifiants
pubmed: 30981115
pii: S2589-0042(19)30088-4
doi: 10.1016/j.isci.2019.03.022
pmc: PMC6461598
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
199-209Subventions
Organisme : NCI NIH HHS
ID : P01 CA140043
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA109874
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA224769
Pays : United States
Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Br J Cancer. 2016 Oct 25;115(9):1017-1023
pubmed: 27685444
Matrix Biol. 2018 Sep;70:20-35
pubmed: 29530483
J Biol Chem. 2000 Jul 21;275(29):21785-8
pubmed: 10801897
J Cell Physiol. 2013 Jul;228(7):1601-9
pubmed: 23359252
Eur Urol. 2016 Aug;70(2):323-31
pubmed: 26924769
Oncol Rep. 2016 Oct;36(4):2177-83
pubmed: 27499367
Cell. 2016 Mar 10;164(6):1226-1232
pubmed: 26967288
J Cell Biol. 2015 Sep 14;210(6):1013-31
pubmed: 26370503
J Cell Biochem. 2017 Jan;118(1):66-73
pubmed: 27232975
J Cell Physiol. 2012 Feb;227(2):751-8
pubmed: 21465482
Cancer Res. 2016 Sep 1;76(17):4948-58
pubmed: 27302169
Oncotarget. 2017 Jan 31;8(5):8043-8056
pubmed: 28009978
Oncotarget. 2016 Mar 22;7(12):14639-58
pubmed: 26840259
J Biol Chem. 2015 Feb 20;290(8):4545-51
pubmed: 25568317
Nat Commun. 2017 Sep 18;8(1):570
pubmed: 28924207
J Cell Physiol. 2010 Jul;224(1):210-7
pubmed: 20333644
Mol Cancer Res. 2016 Nov;14(11):1136-1146
pubmed: 27439335
Cancer Res. 2009 Jul 1;69(13):5374-82
pubmed: 19549894
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Mol Biol Cell. 2017 Nov 1;28(22):2958-2977
pubmed: 28877984
PLoS One. 2013 Oct 09;8(10):e76513
pubmed: 24130778
Cancer Res. 2017 May 1;77(9):2306-2317
pubmed: 28202510
Expert Rev Anticancer Ther. 2008 Jun;8(6):967-74
pubmed: 18533806
J Cell Sci. 2015 Mar 1;128(5):839-52
pubmed: 25663697
FASEB J. 2013 Mar;27(3):1223-35
pubmed: 23233531
J Clin Invest. 2017 Jan 3;127(1):365-374
pubmed: 27918306
Angiogenesis. 2012 Mar;15(1):33-45
pubmed: 22203239
Nat Cell Biol. 2015 Nov;17(11):1412-21
pubmed: 26436690
Front Oncol. 2011 Jul 13;1:17
pubmed: 22645712
Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):E968-77
pubmed: 26858453
PLoS One. 2013 Dec 03;8(12):e81575
pubmed: 24312560
Oncotarget. 2016 Aug 16;7(33):52618-52630
pubmed: 27438371
Oncol Rep. 2016 Nov;36(5):3023-3029
pubmed: 27633518
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Biosci Rep. 2017 Sep 27;37(5):
pubmed: 28842515
Cancer Metastasis Rev. 2014 Sep;33(2-3):595-606
pubmed: 24522479
Matrix Biol. 2019 Apr;77:41-57
pubmed: 30098419
Annu Rev Cell Dev Biol. 2014;30:255-89
pubmed: 25288114
Cancer Res. 2015 Nov 15;75(22):4949-59
pubmed: 26530902
J Cell Biol. 1990 Jan;110(1):175-84
pubmed: 2104857
Semin Cell Dev Biol. 2015 Apr;40:41-51
pubmed: 25721812
Nat Cell Biol. 2015 Jun;17(6):816-26
pubmed: 25985394